RecruitingNCT04715139

Evaluate the Continued Safety and Performance of the Foot and Ankle Products

A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Performance of the Foot and Ankle Products


Sponsor

Arthrex, Inc.

Enrollment

700 participants

Start Date

Dec 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of the registry is to evaluate the continued safety and performance of Arthrex foot and ankle products, including the ProStop® implant for hyperpronated foot; Bio-Compression Screw for reconstruction surgeries of the foot; TRIM-IT Drill Pin® system and/or TRIM-IT Spin Pin™ system for fixation of fractures and fusion (bunionectomy osteotomies) of the foot/ankle; Headless Compression Screws and Compression FT Screws for fixation of small bone fragments of the foot/ankle; DynaNite® nitinol staple for midfoot and hindfoot arthrodeses or osteotomies, first metatarsophalangeal arthrodesis, and mono or bi-cortical osteotomies in the forefoot; BioComposite SutureTak® anchor for medial ankle stabilization; Beveled FT Screws for hallux valgus repair; KreuLock™ screws for ankle fractures; ArthroFLEX® dermal allograft for hallux rigidus arthroplasty; and DualCompression Hindfoot Nail for tibiotalocalcaneal arthrodesis.


Eligibility

Min Age: 2 Years

Inclusion Criteria12

  • Subject requires surgery using Arthrex foot and ankle products included in the registry.
  • Subject is 18 years of age or over (all products except ProStop®).
  • Subject age \>two to 17 years (ProStop® product only).
  • Capable of completing self-administered questionnaires.
  • Willing and able to return for all study-related follow-up visits.
  • Subject or subject's representative signed informed consent and assent, when applicable, and is willing and able to comply with all study requirements.
  • (ArthroFLEX® subjects only):
  • Degenerative or post-traumatic arthritis of the 1st MTP joint with grade 2, 3, or 4.
  • Subjects who require surgical intervention or are medically indicated for an arthrodesis or arthroplasty of the 1st MTP.
  • DualCompression Hindfoot Nail subjects only:
  • The participant must have instability, arthritis, rigid deformity, or severe foot or ankle deformity necessitating tibiotalocalcaneal arthrodesis, commonly referred to as TTC arthrodesis.
  • The participant should be undergoing treatment with the Arthrex DualCompression Hindfoot Nail, either as a primary procedure or as a revision surgery, per standard of care

Exclusion Criteria23

  • Insufficient quantity or quality of bone.
  • Blood supply limitations and previous infections, which may retard healing.
  • Foreign-body sensitivity.
  • Any active infection or blood supply limitations.
  • Conditions that tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period.
  • Subjects that are skeletally immature (except for ProStop®).
  • Subject is considered from vulnerable population (i.e., child, prisoner, pregnant).
  • Subjects who are contraindicated for these devices.
  • Subject is currently receiving compensation or benefits due to a work-related injury or illness under any applicable occupational injury or disability program.
  • Subject has a planned or scheduled additional surgery on the affected or contralateral lower extremity within the course of the study.
  • (® Nitinol Staple Subjects only):
  • Subjects who have a comminuted bone surface that would not allow for staple placement as required by the DynaNite® Nitinol Staples directions for use.
  • Subjects who have pathologic bone conditions such as osteopenia that would impair the ability to securely fix the implant as required by the DynaNite® Nitinol Staples directions for use.
  • (ArthroFLEX® subjects only):
  • Additional ipsilateral lower limb pathology that requires active treatment.
  • Bilateral degenerative or post-traumatic arthritis of the 1st MTP joints that would require simultaneous treatment of both MTP joints.
  • Diagnosis of gout.
  • Any significant bone loss, avascular necrosis, and/or large osteochondral cyst (\>1cm) of the 1st MTP joint.
  • Lesions greater than 10mm in size.
  • Hallux varus to any degree, or hallux valgus \>20 degrees.
  • (DualCompression Hindfoot Nail subjects only):
  • Requiring only a tibiotalar or subtalar arthrodesis
  • Patient requires bulk allograft or metal spacer implant to fill large bony defect and aid in limb salvage

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEProducts listed in Group/Cohort Description

Depending on approved indication per product


Locations(7)

UC Davis Medical Center

Sacramento, California, United States

Northwestern University

Chicago, Illinois, United States

TOA Research Foundation

Nashville, Tennessee, United States

Barrett Podiatry

San Antonio, Texas, United States

Atlantic Orthopaedic Specialists

Virginia Beach, Virginia, United States

OrthoPedes

Duisburg, Germany

Dr Haroun Mahomed Orthopaedic Practice

Durban, South Africa

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04715139